Share this article on:

Immune reconstitution inflammatory syndrome: incidence and implications for mortality

Novak, Richard M.a; Richardson, James T.b; Buchacz, Katec; Chmiel, Joan S.d; Durham, Marcus D.c; Palella, Frank J.d; Wendrow, Andreaa; Wood, Kathyb; Young, Benjamine,f; Brooks, John T.cthe HIV Outpatient Study (HOPS) Investigators

doi: 10.1097/QAD.0b013e3283511e91
Clinical Science

Objective: To describe incidence of immune reconstitution inflammatory syndrome (IRIS) and its association with mortality in a large multisite US HIV-infected cohort applying an objective, comprehensive definition.

Design: We studied 2 610 patients seen during 1996–2007 who initiated or resumed highly active combination antiretroviral therapy (cART) and, during the next 6 months, demonstrated a decline in plasma HIV-RNA viral load of at least 0.5 log10 copies/ml or an increase of at least 50% in CD4 cell count per microliter. We defined IRIS as the diagnosis of a type B or C condition [as per the Centers for Disease Control and Prevention (CDC) 1993 AIDS case definition] or any new mucocutaneous disorder during this same 6-month period.

Methods: We assessed the incidence of IRIS and evaluated risk factors for IRIS using conditional logistic regression and for all-cause mortality using proportional hazards models.

Results: We identified 370 cases of IRIS (in 276 patients). Median and nadir CD4 cell counts at cART initiation were 90 and 43 cells/μl, respectively; median viral load was 2.7 log10 copies/ml. The most common IRIS-defining diagnoses were candidiasis (all forms), cytomegalovirus infection, disseminated Mycobacterium avium intracellulare, Pneumocystis pneumonia, varicella zoster, Kaposi's sarcoma and non-Hodgkin lymphoma. Only one case of Mycobacterium tuberculosis was observed. IRIS was independently associated with CD4 cell count less than 50 cells/μl vs. at least 200 cells/μl [odds ratio (OR) 5.0] and a viral load of at least 5.0 log10 copies vs. less than 4.0 log10 copies (OR 2.3). IRIS with a type B-defining or type C-defining diagnosis approximately doubled the risk for all-cause mortality.

Conclusion: In this large US-based HIV-infected cohort, IRIS occurred in 10.6% of patients who responded to effective ART and contributed to increased mortality.

Supplemental Digital Content is available in the text

aUniversity of Illinois, Chicago, Illinois

bCerner Corporation, Vienna, Virginia

cCenters for Disease Control and Prevention (CDC), Atlanta, Georgia

dFeinberg School of Medicine, Northwestern University, Chicago, Illinois

eRocky Mountain CARES/DIDC, Denver, Colorado, USA

fHealth Connections International, Amsterdam, The Netherlands.

Correspondence to Richard M. Novak, MD, Professor of Medicine, University of Illinois, 808 South Wood Street, M/C 735, Chicago, IL 60612, USA. Tel: +1 312 996 6763; fax: +1 312 413 1657; e-mail:

Received 16 July, 2011

Revised 27 December, 2011

Accepted 6 January, 2012

Data presented previously as an abstract at the 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; July 2009; Cape Town, South Africa.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (

Back to Top | Article Outline


Treatment of HIV infection usually results in a variable degree of immune reconstitution accompanied by a reduction in the risk of opportunistic infections. In some instances, however, a paradoxical worsening of an existing opportunistic infection or the emergence of a new opportunistic infection can occur after initiation of antiretroviral therapy (ART). This type of event, termed immune reconstitution inflammatory syndrome (IRIS), has been reported most commonly in association with mycobacterial infections [Mycobacterium tuberculosis infection (TB) and disseminated Mycobacterium avium complex (MAC)] [1,2], but has also been reported with many other opportunistic infections, including those caused by fungi (e.g., Pneumocystis pneumonia (PCP), toxoplasmosis, coccidioidomycosis], viruses [e.g., hepatitis B virus (HBV) and hepatitis C virus (HCV), cytomegalovirus (CMV) infection, varicella zoster virus (VZV), progressive multifocal leukoencephalopathy], and parasites (e.g. leishmaniasis). An event has typically been considered IRIS, and not a new opportunistic infection, if it occurs within the first 4–8 weeks of ART initiation; however, events attributed to IRIS have occurred later [3–10] (reviewed in [11–14]). With the exception of IRIS in the context of TB [15], there has been no unifying definition with which to describe this entity and define its scope. Reports have varied both in definition of immune reconstitution and the scope of conditions considered related to this event. As a result, comparisons of the incidence and risk factors for IRIS across reports are difficult. Using data from a large, long-standing, and well characterized prospective cohort of HIV-infected adults, we explored IRIS incidence, risk factors, and consequences using a broad definition of IRIS that could be standardized for comparative reporting. We included as IRIS-defining events all AIDS-defining illnesses and a series of HIV-related and other (e.g. autoimmune) conditions previously reported in association with recovery of immune function during ART.

Back to Top | Article Outline


The HIV Outpatient Study

The HIV Outpatient Study (HOPS) is an open, prospective cohort study of HIV-infected patients seen at 10 university and private HIV specialty clinics in eight US cities since 1993 [16]. Patient data, including socio-demographic characteristics and all diagnoses, treatments, and laboratory values, are abstracted from medical charts and entered into an electronic database for central processing and analysis. All HOPS clinicians have extensive experience treating HIV-infected patients. Since its inception, the HOPS protocol has been reviewed annually and approved by the Centers for Disease Control and Prevention (CDC) (Atlanta, Georgia, USA), Cerner Corporation (Vienna, Virginia, USA), and each local site's institutional review board; all participants have provided written, informed consent.

Back to Top | Article Outline

Study population and inclusion criteria

We included HOPS patients who between 1 January 1996 and 31 December 2007 were antiretroviral-naive and initiated highly active combination ART (cART, defined below); receiving antiretrovirals in a regimen that did not qualify as cART and changed to a cART regimen; or virologically failing or discontinued a cART regimen and started a new cART regimen. Rather than requiring a minimum follow-up period (e.g. 180 days), which might have excluded IRIS events occurring before the minimum observation period had elapsed, we instead required each patient to have viral load values recorded at baseline and on at least one occasion during the initial 180 days of follow-up to show evidence of an adequate response to cART, defined as either a 0.5 log10 copies/ml or greater decrease in viral load within 6 months after initiating a new or different cART regimen or, in the absence of sufficient viral load reduction, by a 50% or greater increase in CD4 cell count during this same period. These criteria applied to both those who did and did not develop an IRIS-related condition.

Back to Top | Article Outline

Definitions of predictor variables

We defined cART per standard criteria [16]. Baseline was defined as the date a new or different cART regimen was initiated. Baseline plasma HIV-RNA viral load and CD4 cell count were defined as the values closest to the start of this regimen within the preceding 180 days; patients lacking these data were excluded. Follow-up values for plasma HIV-RNA and CD4 cell count were taken as the measurements that occurred within the first 180 days after the start of cART regimen and prior to the end of the regimen.

Chronic co-infection with HBV or HCV (not considered IRIS-defining events) was defined based on a positive value for any of the following tests performed any time prior to baseline and up to 180 days thereafter: HBV surface antigen, HBVe antigen, quantitative or qualitative HBV or HCV plasma viral load, HCV antibody, or HCV genotype (i.e., type specified). Mycobacterium tuberculosis exposure was defined as a diagnosis of TB, a positive TB skin test, or a positive interferon-γ release assay any time prior to baseline and up to 7 days thereafter.

Back to Top | Article Outline

Definitions of outcome variable

In addition to IRIS with a type B-defining or type C-defining diagnosis (per 1993 surveillance case definition for AIDS) [17], we included select autoimmune disorders and mucocutaneous conditions (see below) not otherwise classified as type B or C, but reported as associated with IRIS in the literature or by extrapolation might possibly be associated with IRIS. Accordingly, we defined a case of IRIS as a patient who developed type B or C illness [17], an autoimmune disorder, or a mucocutaneous condition not otherwise classified as type B or C between 7 and 180 days after initiating the qualifying cART regimen. Our initial list of diagnoses of autoimmune disorders that were IRIS-defining was broadly inclusive: Crohn's disease, idiopathic thrombocytopenic purpura, Grave's disease, Hashimoto's thyroiditis, systemic lupus erythematosis, sarcoidosis, Sjogren's syndrome, myasthenia gravis, Raynaud's disease, rheumatoid arthritis, Addison's disease, Guillian–Barre syndrome, pernicious anemia, Wegener's granulomatosis, vitiligo, or ankylosing spondylitis. We also included in the outcome definition new diagnoses of any of the following mucocutaneous conditions not otherwise classified as type B or C: anogenital Herpes simplex virus infection, condylomata, folliculitis, tinea at any site, and molluscum contagiosum, all previously reported as conditions thought to be associated with IRIS [18–20]. We analyzed all IRIS events combined and then separately type B and C vs. mucocutaneous conditions. Diagnoses were defined as recurrent if 90 days had passed between the end date of the diagnosis’ first occurrence and the start of its second occurrence. Diagnoses recurring fewer than 90 days from the stop date of a prior occurrence were not included. We restricted analyses of IRIS to conditions that were diagnosed after initiation of cART (i.e. not apparent at the time of cART initiation). We did not evaluate episodes of paradoxical worsening of a preexisting opportunistic infection after initiation of cART due to lack of existing standardized data in the HOPS to quantify if the severity of a condition worsened. For wasting (≥10% weight loss), we calculated each patient's percentage weight change between their heaviest weight measured in the year prior to baseline and their subsequent weight measured following initiation of cART. We used wasting to define a case of IRIS only in those cases in which no other IRIS-defining events were present.

Back to Top | Article Outline

Analysis methods

For estimating incidence of IRIS, patients who experienced IRIS contributed person-years of observation (pyo) from the time of initiating the qualifying cART regimen to the date of the IRIS-defining diagnosis, which by definition occurred within the first 6 months of therapy. Patients who did not experience IRIS contributed pyo from the time of initiating the qualifying cART regimen to the date 6 months later; regimens of shorter duration were censored at their end date. Individual patients could contribute pyo from multiple qualifying cART regimens and, therefore, more than one IRIS event. The denominator equaled the sum of pyo contributed by all patients meeting the inclusion criteria. The numerator equaled the sum of IRIS cases observed. We assessed crude differences in time to IRIS by type of IRIS event, and time from baseline to death for patients who did and did not experience IRIS, using the Wilcoxon rank-sum test.

We also conducted a case–control analysis to further assess risk factors for IRIS. Cases and controls were matched on the year a qualifying cART regimen was started and on ART status (naive vs. experienced) at the start of that regimen. We randomly selected four controls for each IRIS case, using incidence density sampling methodology. In our multivariable conditional logistic regression models, we included all factors explored in univariate analyses: viral load and CD4 cell count, HIV transmission risk group, race/ethnicity, age, sex, hepatitis co-infection status, and history of TB exposure (e.g. positive skin test) or known TB infection.

Finally, we investigated whether IRIS was associated with increased mortality in our study cohort using Cox proportional hazards analyses. The start of observation was the start date of the qualifying cART regimen during which a patient developed first IRIS event; it was the start of the first qualifying cART regimen for patients who did not develop any IRIS events. The end of observation was either last HOPS contact, date of death, or 31 March 2008. We analyzed deaths documented within 180 days of last HOPS contact; patients not known to have died in that period were assumed alive.

All analyses were performed using SAS version 9.1 (SAS Institute, Cary, North Carolina, USA).

Back to Top | Article Outline


Among 8 712 HOPS patients in the HOPS database as of 31 March 2008, we identified 2 610 patients meeting criteria for analyses. This study population included 81.0% men, 41.5% patients of nonwhite race/ethnicity, and 30.5% patients who were antiretroviral-naive [median age (interquartile range, IQR) at first qualifying cART: 40 (35, 46) years, median nadir CD4 cell count: 187 (54, 320) cells/μl].

The 2 610 patients contributed 3 557 qualifying cART regimens to analyses of IRIS rates. During follow-up, IRIS was documented during 370 (10.4%) cART regimens and affected 276 (10.6%) of 2 610 patients (Table 1). One hundred and seventy-two (46.5%) of the 370 cases of IRIS were type B or C events, affecting 6.6% of patients; 198 (53.5%) events were mucocutaneous manifestations, and there were no autoimmune disorders other than idiopathic thrombocytopenic purpura, which was already captured as type B event. There were 28 patients with multiple IRIS events.

Table 1

Table 1

Candidiasis of any type was the most common IRIS-defining event (Table 2). Other common IRIS events were CMV end-organ disease, MAC, and PCP. Common mucocutaneous events not otherwise classified as type B or C included anogenital Herpes simplex, condylomata, folliculitis, tinea, and molluscum contagiosum. The median time from the start of the qualifying cART regimen to an IRIS event was 63 days (range: 7–170, IQR: 28–120): for the 81 type B events, median 65 days (range: 8–169, IQR: 31–132), for the 91 type C events, median 40 days (range: 8–161, IQR: 17–92), and for the 198 mucocutaneous events, median 73 days (range: 7–170, IQR: 35–122) (P < 0.001 for difference by type of event).

Table 2

Table 2

Overall, the incidence of IRIS by our definition was 25.1 per 100 pyo (Table 3), and it was higher for patients with lower baseline CD4 cell count and with higher baseline viral load. Incidence of IRIS type B and C events only (i.e., excluding mucocutaneous events) was 12.0 per 100 pyo [with 95% confidence interval (CI): 10.4, 13.9].

Table 3

Table 3

In univariate conditional logistic regression analyses, development of IRIS was associated (P < 0.05) with female sex; nonwhite race/ethnicity; IDU or heterosexual risk category compared with MSM; baseline viral load at least 4 log10 copies/ml; and baseline CD4 cell count below 200 cells/μl; whereas age of 50 years and older was protective against developing IRIS (Table 4). In analyses limited to type B and C events, in addition to stronger associations with low CD4 cell count and high viral load, HCV or HBV infection was also associated with increased odds of IRIS (supplemental on-line Table 4a, For mucocutaneous events, factors associated with IRIS on univariate analyses included nonwhite race/ethnicity, heterosexual risk category, baseline viral load at least 5 log10 copies/ml and baseline CD4 cell count less than 200 cells/μl (supplemental on-line Table 4b,

Table 4

Table 4

In multivariable analyses, the odds of any IRIS event were 2.3 times as high among patients with a baseline viral load at least 5 log10 copies/ml compared with baseline viral load less than 4 log10 copies/ml and 5.0 and 2.2 times as high among those with baseline CD4 cell counts less than 50 and 50–199 cells/μl, respectively, compared with those with baseline CD4 cell counts of at least 200 cells/μl (Table 4). Patients who were heterosexual or of nonwhite race also had higher odds of IRIS. In analyses limited to type B and C IRIS events, the adjusted associations with low CD4 cell count and high viral load were even stronger, whereas there was less evidence for association with HBV or HCV (supplemental Table 4a, For mucocutaneous events, these associations remained and age at least 35 years was also protective (supplemental Table 4b,

Among the 2 610 patients included in the analyses, we observed 263 deaths: 64 deaths among 276 patients who experienced IRIS, 199 deaths among those who did not. Among patients who died, the median time from baseline to death was 40.6 months (IQR: 19.2–90.2) and 53.1 months (IQR: 23.2–95.5), respectively, for persons who did vs. did not experience IRIS-defining events (P = 0.009). In univariate proportional hazards analyses, the mortality was significantly higher after the occurrence of a type B or type C IRIS event, but was not associated with mucocutaneous events (Table 5). Other baseline factors associated with mortality in univariate analysis included non-Hispanic black or Hispanic race/ethnicity, age more than 40 years, IDU history, viral load more than 5 log10 copies/ml, low CD4 cell count, a history of an AIDS-defining diagnosis, initiation of cART between 1996 and 2000, having public or other insurance (compared with private), and prior antiretroviral experience (Table 5). After adjusting for these covariates in multivariable analysis, type B and C IRIS events remained significantly associated with mortality (hazard ratios 2.3 and 2.4, respectively), whereas mucocutaneous events were associated with a reduced risk of mortality (hazard ratio 0.54, 95% CI: 0.32, 0.92, Table 5).

Table 5

Table 5

In sensitivity analyses, restricted to 1 518 patients who experienced suppression of viral load less than 1000 copies/ml on their first qualifying cART regimen (this viral load limit was chosen to account for the range of sensitivities of the various viral load assays used over the period of study), the incidence rate of IRIS (n = 122 events) was 18.7 per 100 pyo (95% CI: 15.6, 22.2) and was not statistically different for patients who were baseline antiretroviral-naive vs. antiretroviral-experienced (data not shown). In the same subset of patients, type C events remained associated with increased mortality in analyses controlling for viral load, CD4 cell count, and age (hazard ratio: 3.3, 95% CI: 1.6, 6.8); type B or mucocutaneous events were not associated with survival in this smaller subset of patients who experienced virologic suppression.

Back to Top | Article Outline


We have developed a definition for IRIS that is broader than those used in earlier descriptions of this entity and have applied it to a substantially larger observational cohort than previous studies. Broadening the definition to include type B and C events and mucocutaneous conditions increased the percentage of affected patients from 6.6 to 10.6%. The incidence of IRIS, using this broad inclusive definition, is lower than that in prior smaller cohort studies from single institutions in industrialized countries, some of which focused on subsets of opportunistic infections or included subgroups with demographic profiles more consistent with a developing country [2,5,21]. Our observed incidence may be lower for a number of reasons. First, although we and others observed that risk for IRIS was increased among persons with low CD4 cell count and elevated viral load, over 50% of the ‘qualifying cART regimens’ in our analyses had baseline CD4 cell count at least 200 cells/μl and more than one-fifth had baseline viral load less than 10 000 copies/ml. Using the large HOPS dataset, we were able to demonstrate that the incidence of IRIS varies by baseline CD4 cell count, which may explain the higher rates reported in prior studies focused on persons with CD4 cell count less than 200 cells/μl. Second, prevalence of TB in the United States is vastly lower than that in other regions where it is both a major AIDS-defining condition and IRIS-defining condition. Finally, and perhaps most important, our definition of an IRIS-defining event, in contrast to some previous studies, did not include paradoxical worsening of an existing condition. The nature of our data source (chart abstraction of diagnoses and laboratory values), like many observational HIV cohort studies, did not permit reliable characterization of the course of disease or change in the quality of illness.

The HOPS draws patients only from the United States, reflecting HIV-related conditions more often seen in industrialized countries. As a result, it is not surprising that mycobacterial diseases, and particularly TB, were rare as IRIS events in our cohort, whereas candidiasis was the preponderant event. In observational cohorts from Africa and Asia, TB is consistently the most common IRIS-related event [22–25]. In the largest such study to date among 423 treatment-naive South Africans, 44 (10.4%) patients developed IRIS for an incidence rate of 25.1 cases per 100 pyo, with 18 patients developing tuberculosis [22]. In a prospective study from Ethiopia among 186 HIV-infected patients, with a mean CD4 cell count of 123 cells/μl, and in whom more than 60% had an opportunistic infection prior to or at the time of initiation of cART, 32 (17.2%) patients experienced IRIS, including 22 who developed TB [23].

Our study contributes to the available evidence that IRIS-related events may fall outside the CDC case definition for HIV-associated and AIDS-defining events. These diagnoses have included oral manifestations such as parotid enlargement or candidiasis [26,27] and autoimmune diseases, such as autoimmune hepatitis [28], ulcerative colitis [29], sarcoidosis [30], Grave's disease [31], and Reiter's syndrome [32]. Only one such event was seen in the HOPS cohort. Skin manifestations such as molluscum contagiosum [20], cutaneous warts [19], herpes zoster [33], and genital herpes simplex virus [5,34] have also been observed as IRIS events. In the developing world, entities such as leprosy [35–37] and leishmaniasis [2,3,38] have also been observed.

A novel finding of our study was the striking association of having experienced an IRIS-defining event with an increased risk of death, after adjusting for baseline CD4 cell count. A similar result was observed in a small Mexican cohort, but differs from a South Korean report that found no association of IRIS with mortality [39,40], potentially due to small sample size, shorter duration of follow-up, and differences in the definition of IRIS. In our study, the association between IRIS and increased mortality was evident for both HIV-associated and generally nonlife-threatening (type B) events as well as AIDS-defining and potentially life-threatening events (type C), but was not apparent for mucocutaneous events. Indeed, although mucocutaneous events were not associated with mortality in crude analyses (hazard ratio 0.99), they appeared to be protective for mortality after adjusting for CD4, viral load, and other factors. Most mucocutaneous events are not life threatening and would not be expected to contribute to death, and the appearance of a protective association in adjusted analyses is somewhat surprising and needs to be interpreted cautiously. Whether the mucocutaneous events should be included in the definition of IRIS is less important than to understand that their occurrence carries less clinical significance. We could not establish the relative contributions of individual type B and C events to mortality due to the relatively small number of events observed.

Our study is subject to several additional limitations. Diagnoses of some opportunistic infections in the HOPS do not require laboratory confirmation and some IRIS-defining events could, thus, have been misclassified. As with all observational data, we could not exclude the possibility of residual and unmeasured confounding (e.g. type of cART, adherence to prescribed ART) that might have affected the conclusions. We note that our inclusion criteria were based on virologic and immunologic responses to a new cART regimen regardless of its antiretroviral composition or patient adherence. Analyses using data from other large cohort studies to examine risk factors associated with IRIS and the potential contribution of IRIS to mortality could be helpful in determining whether the associations we observed are valid and generalizable. Further, the diagnoses we considered as IRIS-defining included only conditions endemic to North America and specifically the United States; the distribution of IRIS-defining events and their individual incidence rates likely differ in other regions where characteristics of patients initiating cART and prevalence of opportunistic infections may differ substantially. In our study, we did not evaluate episodes of worsening of a preexisting opportunistic infection after cART initiation (i.e., paradoxical IRIS), because we could not apply standardized criteria for ‘worsening’ of a condition based solely on review of existing medical records. As noted earlier, this limitation may explain why the incidence of IRIS we observed was relatively low compared with some smaller studies in the United States and Europe [2,5,21].

Little is known about the pathophysiologic mechanisms for IRIS. Elevated serum pro-inflammatory biomarkers have been observed both before and after cART initiation in patients who subsequently developed IRIS, findings consistent with the inflammatory nature of the syndrome [41,42]. Some data suggest a role for T-regulatory cells (Tregs) [43]. The observed association of HCV or HBV co-infection with IRIS that was seen in univariate analyses, limited to type B and C events, but that was less apparent in multivariable analysis was unexpected. The effect of chronic viral hepatitis on Treg function may contribute to dysregulation of immune recovery, which could contribute to the emergence of IRIS [44,45]. The implication that co-infections may selectively impact overlapping immune mechanisms for the emergence of IRIS must also be considered in understanding this phenomenon.

In conclusion, as others have observed, we found that IRIS was associated with low CD4 cell count and high viral load at the time of effective cART initiation or resumption. A novel association of IRIS-defining type B and C events with increased risk for subsequent mortality, if supported by other research, might provide another compelling reason for earlier cART initiation. Research to identify the biological mechanisms underlying IRIS may facilitate earlier identification of persons at risk for the condition, as well as effective interventions to prevent it.

Back to Top | Article Outline


The HIV Outpatient Study (HOPS) Investigators include the following persons and sites:

J.T.B., K.B., M.D.D., Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention (NCHSTP), Centers for Disease Control and Prevention (CDC), Atlanta, Georgia; K.C.W., Rose K. Baker, J.T.R., Darlene Hankerson, and Carl Armon, Cerner Corporation, Vienna, Virginia; F.J.P., J.S.C., Carolyn Studney, and Onyinye Enyia, Feinberg School of Medicine, Northwestern University, Chicago, Illinois; Kenneth A. Lichtenstein and Cheryl Stewart, National Jewish Medical and Research Center Denver, Colorado; John Hammer, B.Y., Kenneth S. Greenberg, Barbara Widick, and Joslyn D. Axinn, Rose Medical Center, Denver, Colorado; Bienvenido G. Yangco and Kalliope Halkias, Infectious Disease Research Institute, Tampa, Florida; Douglas J. Ward and Jay Miller, Dupont Circle Physicians Group, Washington, District of Columbia; Jack Fuhrer, Linda Ording-Bauer, Rita Kelly, and Jane Esteves, State University of New York (SUNY), Stony Brook, New York; Ellen M. Tedaldi, Ramona A. Christian, Faye Ruley, and Dania Beadle, Temple University School of Medicine, Philadelphia, Pennsylvania; and R.M.N. and A.W., University of Illinois at Chicago, Chicago, Illinois, USA.

The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention (CDC).

Funding source is contract 200-2001-00133 from the Centers for Disease Control and Prevention (CDC).

Back to Top | Article Outline

Conflicts of interest

There are no conflicts of interest.

Back to Top | Article Outline


1. Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998; 158:157–161.
2. Shelburne SA, Visnegarwala F, Darcourt J, Graviss EA, Giordano TP, White AC Jr, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005; 19:399–406.
3. Posada-Vergara MP, Lindoso JA, Tolezano JE, Pereira-Chioccola VL, Silva MV, Goto H. Tegumentary leishmaniasis as a manifestation of immune reconstitution inflammatory syndrome in 2 patients with AIDS. J Infect Dis 2005; 192:1819–1822.
4. Shelburne SA 3rd, Hamill RJ, Rodriguez-Barradas MC, Greenberg SB, Atmar RL, Musher DW, et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine 2002, 81:213–227.
5. Ratnam I, Chiu C, Kandala NB, Easterbrook PJ. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis 2006; 42:418–427.
6. Martinez JV, Mazziotti JV, Efron ED, Bonardo P, Jordan R, Sevlever G, et al. Immune reconstitution inflammatory syndrome associated with PML in AIDS: a treatable disorder. Neurology 2006; 67:1692–1694.
7. Patel AK, Patel KK, Shah SD, Desai J. Immune reconstitution syndrome presenting with cerebral varicella zoster vasculitis in HIV-1-infected patient: a case report. J Int Assoc Physicians AIDS Care (Chic Ill) 2006; 5:157–160.
8. Godoy MC, Silva CI, Ellis J, Phillips P, Muller NL. Organizing pneumonia as a manifestation of Pneumocystis jiroveci immune reconstitution syndrome in HIV-positive patients: report of 2 cases. J Thorac Imaging 2008; 23:39–43.
9. Mortimer RB, Libke R, Egbalieh B, Bilello JF. Immune Reconstitution inflammatory syndrome presenting as superior vena cava syndrome secondary to coccidioides lymphadenopathy in an HIV-infected patient. J Int Assoc Physicians AIDS Care (Chic Ill) 2008; 7:283–285.
10. von Both U, Laffer R, Grube C, Bossart W, Gaspert A, Gunthard HF. Acute cytomegalovirus colitis presenting during primary HIV infection: an unusual case of an immune reconstitution inflammatory syndrome. Clin Infect Dis 2008; 46:e38–e40.
11. Shelburne SA 3rd, Hamill RJ. The immune reconstitution inflammatory syndrome. AIDS Rev 2003; 5:67–79.
12. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS 2004; 18:1615–1627.
13. Lipman M, Breen R. Immune reconstitution inflammatory syndrome in HIV. Curr Opin Infect Dis 2006; 19:20–25.
14. Murdoch DM, Venter WD, Van Rie A, Feldman C. Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment options. AIDS Res Ther 2007; 4:9.
15. Meintjes G, Lawn SD, Scano F, Maartens G, French MA, Worodria W, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008; 8:516–523.
16. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853–860.
17. Centers for Disease Control and Prevention (CDC). 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992; 41 (RR-17):1–19.
18. Lehloenya R, Meintjes G. Dermatologic manifestations of the immune reconstitution inflammatory syndrome. Dermatol Clin 2006; 24:549–570.vii.
19. Kerob D, Dupuy A, Vignon-Pennamen MD, Bournerias I, Dohin E, Lebbe C. A case of efflorescence of cutaneous warts as a manifestation of immune reconstitution inflammatory syndrome in an HIV-infected patient. Clin Infect Dis 2007; 45:405–406.
20. Pereira B, Fernandes C, Nachiambo E, Catarino MC, Rodrigues A, Cardoso J. Exuberant molluscum contagiosum as a manifestation of the immune reconstitution inflammatory syndrome. Dermatol Online J 2007; 13:6.
21. Robertson J, Meier M, Wall J, Ying J, Fichtenbaum CJ. Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy. Clin Infect Dis 2006; 42:1639–1646.
22. Murdoch DM, Venter WD, Feldman C, Van Rie A. Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. AIDS 2008; 22:601–610.
23. Huruy K, Mulu A, Mengistu G, Shewa-Amare A, Akalu A, Kassu A, et al. Immune reconstitution inflammatory syndrome among HIV/AIDS patients during highly active antiretroviral therapy in Addis Ababa, Ethiopia. Jpn J Infect Dis 2008; 61:205–209.
24. Tansuphasawadikul S, Saito W, Kim J, Phonrat B, Dhitavat J, Chamnachanan S, et al. Outcomes in HIV-infected patients on antiretroviral therapy with tuberculosis. Southeast Asian J Trop Med Public Health 2007; 38:1053–1060.
25. Park WB, Choe PG, Jo JH, Kim SH, Bang JH, Kim HB, et al. Tuberculosis manifested by immune reconstitution inflammatory syndrome during HAART. AIDS 2007; 21:875–877.
26. Ortega KL, Ceballos-Salobrena A, Gaitan-Cepeda LA, Magalhaes MG. Oral manifestations after immune reconstitution in HIV patients on HAART. Int J STD AIDS 2008; 19:305–308.
27. Gaitan Cepeda LA, Ceballos Salobrena A, Lopez Ortega K, Arzate Mora N, Jimenez Soriano Y. Oral lesions and immune reconstitution syndrome in HIV+/AIDS patients receiving highly active antiretroviral therapy. Epidemiological evidence. Med Oral Patol Oral Cir Bucal 2008; 13:E85–E93.
28. O’Leary JG, Zachary K, Misdraji J, Chung RT. De novo autoimmune hepatitis during immune reconstitution in an HIV-infected patient receiving highly active antiretroviral therapy. Clin Infect Dis 2008; 46:e12–e14.
29. Acosta RD, Itzkowitz SL. Immune reconstitution syndrome masquerading as ulcerative colitis in a patient with HIV. Gastrointest Endosc 2008; 68:1197–1198.discussion 1198.
30. Ferrand RA, Cartledge JD, Connolly J, Standish RA, Miller RF. Immune reconstitution sarcoidosis presenting with hypercalcaemia and renal failure in HIV infection. Int J STD AIDS 2007; 18:138–139.
31. Vos F, Pieters G, Keuter M, van der Ven A. Graves’ disease during immune reconstitution in HIV-infected patients treated with HAART. Scand J Infect Dis 2006; 38:124–126.
32. Neumann S, Kreth F, Schubert S, Mossner J, Caca K. Reiter's syndrome as a manifestation of an immune reconstitution syndrome in an HIV-infected patient: successful treatment with doxycycline. Clin Infect Dis 2003; 36:1628–1629.
33. Feller L, Wood NH, Lemmer J. Herpes zoster infection as an immune reconstitution inflammatory syndrome in HIV-seropositive subjects: a review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 104:455–460.
34. Couppie P, Sarazin F, Clyti E, El Guedj M, Vaz T, Sainte-Marie D, et al. Increased incidence of genital herpes after HAART initiation: a frequent presentation of immune reconstitution inflammatory syndrome (IRIS) in HIV-infected patients. AIDS Patient Care STDS 2006; 20:143–145.
35. Kharkar V, Bhor UH, Mahajan S, Khopkar U. Type I lepra reaction presenting as immune reconstitution inflammatory syndrome. Indian J Dermatol Venereol Leprol 2007; 73:253–256.
36. Kar HK, Sharma P. Does concomitant hiv infection has any epidemiological, clinical, immunopathological and therapeutic relevance in leprosy?. Indian J Lepr 2007; 79:45–60.
37. Trindade MA, Valente NY, Manini MI, Takahashi MD, Anjos CF, Benard G, et al. Two patients coinfected with Mycobacterium leprae and human immunodeficiency virus type 1 and naive for antiretroviral therapy who exhibited type 1 leprosy reactions mimicking the immune reconstitution inflammatory syndrome. J Clin Microbiol 2006; 44:4616–4618.
38. Antinori S, Longhi E, Bestetti G, Piolini R, Acquaviva V, Foschi A, et al. Postkala-azar dermal leishmaniasis as an immune reconstitution inflammatory syndrome in a patient with acquired immune deficiency syndrome. Br J Dermatol 2007; 157:1032–1036.
39. Hoyo-Ulloa I, Belaunzaran-Zamudio PF, Crabtree-Ramirez B, Galindo-Fraga A, Perez-Aguinaga ME, Sierra-Madero JG. Impact of the immune reconstitution inflammatory syndrome (IRIS) on mortality and morbidity in HIV-infected patients in Mexico. Int J Infect Dis 2011; 15:e408–e414.
40. Park WB, Choe PG, Jo JH, Kim SH, Bang JH, Kim HB, et al. Immune reconstitution inflammatory syndrome in the first year after HAART: influence on long-term clinical outcome. AIDS 2006; 20:2390–2392.
41. Sereti I, Rodger AJ, French MA. Biomarkers in immune reconstitution inflammatory syndrome: signals from pathogenesis. Curr Opin HIV AIDS 2010; 5:504–510.
42. Porter BO, Ouedraogo GL, Hodge JN, Smith MA, Pau A, Roby G, et al. d-Dimer and CRP levels are elevated prior to antiretroviral treatment in patients who develop IRIS. Clin Immunol 2010; 136:42–50.
43. Cianchetta-Sivori M, Raso S, Fernandez-Guerrero M, Gorgolas M, Garcia R. Do CD8(+)CD25(+) cells predict immune reconstitution syndrome in HIV-positive patients who begin HAART?. AIDS 2007; 21:2347–2349.
44. Alatrakchi N, Koziel M. Regulatory T cells and viral liver disease. J Viral Hepat 2009; 16:223–229.
45. Peng G, Li S, Wu W, Sun Z, Chen Y, Chen Z. Circulating CD4+ CD25+ regulatory T cells correlate with chronic hepatitis B infection. Immunology 2008; 123:57–65.

HAART; HIV; immune reconstitution inflammatory syndrome; mortality; opportunistic infections; risk factors; United States

© 2012 Lippincott Williams & Wilkins, Inc.